Research
Hormonal
Tirzepatide, a GLP1:GIP dual agonist, provides superior glycemic and weight-loss efficacy compared to placebo, achieving >20% body weight loss in 57% of participants at the highest dose over 72 weeks.
Tirzepatide, a dual GLP1:GIP agonist, has demonstrated superior efficacy in Phase 3 trials, achieving over 20% body weight loss in more than half of participants at the highest dose over 72 weeks with minimal side effects. This makes it a highly effective option for managing diabesity compared to placebo.
GoodSupportsHIGH confidence
Phase 3 trials of 2,539 participants demonstrated the superior glycemic and weight-loss efficacy of Tirzepatide compared with placebo, with its highest dose providing >20% body weight loss in the majority (57%) of participants in a 72-week trial, with minimal adverse effects [42].
Why this rating
Based on Phase 3 trials with >2,500 participants, indicating robust clinical data.
Source
Designer GLP1 poly-agonist peptides in the management of diabesity
Laura Statham et al. · Expert Review of Endocrinology & Metabolism · 2023
DOI 10.1080/17446651.2023.2204976
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP1:Gcg dual agonists (Mazdutide and Cotadutide) show promise in weight loss and glycemic control, with additional benefits for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).Moderate
- GLP1:GIP:Gcg triple agonists (SAR441255) show potential for weight loss and neurological benefits, including improved memory in mouse models of TBI and Alzheimer's disease.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →